Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Precision Biosciences Inc (NQ: DTIL ) 9.020 +0.460 (+5.37%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 77,348 Open 8.670 Bid (Size) 9.000 (4) Ask (Size) 9.120 (2) Prev. Close 8.560 Today's Range 8.600 - 9.140 52wk Range 7.970 - 19.43 Shares Outstanding 113,793,338 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Precision BioSciences to Report Third Quarter Results on November 4, 2024 October 29, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 October 28, 2024 From Precision BioSciences, Inc. Via Business Wire Performance YTD -18.74% -18.74% 1 Month -1.42% -1.42% 3 Month -3.22% -3.22% 6 Month -14.26% -14.26% 1 Year -24.83% -24.83% More News Read More Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress October 24, 2024 From Precision BioSciences, Inc. Via Business Wire Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings) May 16, 2024 Via Benzinga Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B October 24, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences October 21, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress October 16, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference October 03, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B September 30, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) September 20, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution September 12, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference September 04, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal September 03, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis August 09, 2024 From Precision BioSciences, Inc. Via Business Wire 7 Biotech Stocks to Buy for Their Game-Changing Potential August 08, 2024 Via InvestorPlace Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update August 01, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Participate in Upcoming August Investor Conferences July 31, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Report Second Quarter Results on August 1, 2024 July 29, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit July 08, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Announces its Addition to the Russell Microcap® Index July 01, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025 June 27, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness June 20, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress June 05, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Participate in Upcoming June Investor Conferences May 30, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) May 17, 2024 From Precision BioSciences, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
